<DOC>
	<DOCNO>NCT00279201</DOCNO>
	<brief_summary>This study compare insulin lispro low mixture [ LM ] insulin glargine combination patient 's oral diabetes medicine , ability control blood sugar patient type 2 diabetes compare insulin lispro LM insulin glargine regard length time overall blood sugar control . This study also determine whether safety insulin lispro LM side effect might associate different observed insulin glargine , combination patient 's oral diabetes medication . The addendum study ( Intensification Addendum ) compare different insulin treatment work control blood sugar patient whose diabetes could control either insulin lispro LM insulin glargine .</brief_summary>
	<brief_title>The DURABLE Trial : Evaluating Durability Starter Insulin Regimens Patients With Type 2 Diabetes ( IOOV )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Must type 2 diabetes . Must least 30 less 80 year age time Visit 1 . Must least two oral antidiabetes medication least 90 day . Must HbA1c 1.2 2.0 time upper limit normal reference range local lab . Must use insulin regular basis last 12 month . Must one episode severe hypoglycemia last 24 week . Must body mass index ( BMI ) great 45 ( morbid obesity ) . Must clinically significant hematologic , oncologic , renal , cardiac , hepatic , gastrointestinal disease . Must pregnant intend get pregnant course study .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>diabetes</keyword>
	<keyword>type 2</keyword>
</DOC>